Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:PFE
Pfizer Inc (PFE)
26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
Financials 
Technical Analysis 0
BUY
A tough BUY, but given the valuation, if you have a 3/5 year time horizon the positives outweigh the negatives.
George LougheryOwned
biotechnologypharmaceutical
WEAK BUY
Big pharmas have suffered because generics have come out of nowhere and have moved up to 50% of their business. The shine is coming off these companies and their credibility. Now trading at 12 X earnings and have a ton of cash, so could be buying back shares and improve its dividend. Good yield, but limited growth.
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Oct 26/04. Down 11%.) About a 50% differential between their model price and its present price. In their top 10. Has great value.
Brian Acker, CAOwned
biotechnologypharmaceutical
BUY
Has been hurt by the Cox-2 inhibitor problem which is in their Celbrex and Bextra. Pharmaceutical stocks in general have all been poor performers and valuations have become more reasonable, so is probably OK to start looking at them. Prefers Bristol Myers as you get a nice size dividend as they wait for a pick up.
biotechnologypharmaceutical
TOP PICK
(A Top Pick Oct 26/04. Down 8%.) Model price is $39. Totally mispriced. Should be a portion of everybody's portfolio. Looking out a year, you should make good money off it.
Brian Acker, CAOwned
biotechnologypharmaceutical
TOP PICK
Quality at a discount. There will be a lot of opportunity for upward surprises and multiple expansion. Trades at 11.7 X next year's earnings which is a 22% discount to its peer group. Have a wide and deep pipeline.
Paul Harris, CFAOwned
biotechnologypharmaceutical
DON'T BUY
Companies like Pfizer and Merck have been coming apart for quite awhile. Growth rate has gone from 30% to low single digits. When this happens, the P/E has to contract. There are more sellers than buyers. One of the few that is doing better is Schering AG. Growth rate is accelerating and have a good line up of drugs.
biotechnologypharmaceutical
TOP PICK
Of all the drug companies put together, this company has the strongest pipe line. This is a mispriced asset. When you lok at the earnings, the balance sheet and where interest rates are, it's worth $50.
Brian Acker, CAOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
